Investors Gear Up to Lead Class Action Against Allarity Therapeutics
LOS ANGELES, Oct. 31, 2024 /PRNewswire/ — Glancy Prongay & Murray LLP (“GPM”) has announced that investors with significant losses may lead a class action lawsuit for securities fraud against Allarity Therapeutics, Inc. (“Allarity” or the “Company”) ALLR.
Class Period: May 17, 2022 – July 19, 2024
Lead Plaintiff Deadline: November 12, 2024
If you are interested in becoming the lead plaintiff in the Allarity lawsuit, please submit your contact details at www.glancylaw.com/cases/Allarity-Therapeutics-Inc/. You may also reach out to Charles H. Linehan of GPM at 310-201-9150, toll-free at 888-773-9224, or via email at shareholders@glancylaw.com for additional information on your rights.
The complaint claims that during the Class Period, the Defendants did not inform investors that: (1) they exaggerated the Dovitinib NDA’s regulatory potential; (2) Allarity and three former officers participated in illegal activities concerning the Dovitinib NDA and Dovitinib-DRP PMA; (3) this misconduct left the Company vulnerable to intensified regulatory investigations and potential enforcement actions, causing notable legal and reputational damage; (4) after Allarity announced it was under investigation regarding the Dovitinib NDA, the Company minimized the likelihood of any enforcement actions resulting from that investigation; and (5) these misleading positive statements about Allarity’s business performance were not founded on truthful or reasonable bases throughout the relevant periods.
For ongoing updates, follow us on LinkedIn, Twitter, or Facebook.
To join the class action, no immediate action is necessary. You may choose to hire a lawyer or simply remain an absent member of the class. For more details about this class action or if you have questions regarding this announcement or your rights, contact Charles Linehan, Esquire, of GPM, located at 1925 Century Park East, Suite 2100, Los Angeles, California 90067. He can be reached at 310-201-9150, toll-free at 888-773-9224, or via email at shareholders@glancylaw.com. When contacting by email, please provide your mailing address, phone number, and number of shares purchased.
This press release may be regarded as Attorney Advertising in certain jurisdictions based on applicable laws and ethical guidelines.
Contacts
Glancy Prongay & Murray LLP, Los Angeles
Charles Linehan, 310-201-9150 or 888-773-9224
shareholders@glancylaw.com
www.glancylaw.com
View original content to download multimedia: https://www.prnewswire.com/news-releases/allr-investors-have-opportunity-to-lead-allarity-therapeutics-inc-securities-fraud-lawsuit-302293493.html
SOURCE Glancy Prongay & Murray LLP
Market News and Data brought to you by Benzinga APIs